NCT06161376Recruiting
Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multiple Sclerosis
Prospective Study Evaluating the Role of Urinary Sphingosine 1-Phosphate as a Biomarker for Detrusor Hyperactivity in Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 31 Dec 2025
Brief summary (registry, in English)
This study aims to establish a link between urinary Sphingosine 1-Phosphate (S1P) levels and detrusor activity in multiple sclerosis (MS) patients. MS often involves urological symptoms, primarily overactive bladder. The gold standard for evaluation and treatment monitoring is invasive urodynamic testing. Preliminary research at Toulouse University Hospital suggests urinary S1P levels may be a potential biomarker for detrusor activity in MS. This study aims to confirm this potential biomarker's utility.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 29 Nov 2023
- Start date
- 4 Dec 2023
- Primary completion date
- Dec 2027
- Lead sponsor
- University Hospital, Toulouse
- Diseases
- Multiple sclerosis
- NCT number
- NCT06161376
What you commit to
- Study type: Observational
- Planned participants: 400
- From 4 Dec 2023 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Untreated urinary tract infection at the time of inclusion
- Known anatomical subvesical obstruction Known pelvic floor disorder Urothelial carcinoma Interstitial cystitis Augmentation cystoplasty
Other
- Pregnant or lactating females
- Patients under legal guardianship
Who the study is looking for
- French residents enrolled in the social security system
- Patients diagnosed with multiple sclerosis (according to McDonald 2017 criteria), whether receiving treatment or not
- Patients scheduled for urodynamic assessment as part of their management
Age in the registry: 18 years to 75 years · Sex: All
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Toulouse Hospital Coordinator of this site? Confirm its status | Toulouse | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.